Truffle Capital scores € 390m for two funds

December 20, 2019

Paris-based VC firm Truffle Capital has secured €250 million in commitments for its BioMedTech fund and a further €140 million for a vehicle focused on the fintech and insurtech sectors. The former will be used to back a dozen startups, primarily in France, that are developing medical devices and minimally invasive medicine.

The latter will be used to target up to 15 companies developing AI and blockchain-based products for the banking and insurance industries.

ALSO TO BE DISCOVERED

December 19, 2019

Truffle Capital Raises € 250m Fund to Launch Life Science Startups

December 18, 2019

Truffle Capital successfully raises nearly €400 million for new Venture Capital funds. Funds backed by top-tier French and international institutional investors

December 3, 2019

Affluent Medical announces first patient implanted in optimise II pivotal clinical study for Kalios, the minimally invasive mitral valve repair ring

December 3, 2019

Carbios receives € 1.4M from ADEME following the success of the first milestone of its CE-PET research project

November 21, 2019

Abivax Receives French Regulatory Authority (ANSM) Approval to Include French Study Sites in its Phase 2b Ulcerative Colitis Clinical Trial and Provides a Progress Update of the ABX464 Clinical Development Plan in other Inflammatory Diseases

November 21, 2019

Consortium with Nestlé Waters, PepsiCo and Suntory Beverage & Food

November 19, 2019

Biotech SME Awards 2019: Recognising breakthrough science in Europe

October 21, 2019

ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference

October 21, 2019

Impressive 12-month Efficacy and Safety Data from ABX464

September 12, 2019

FDA approval to launch a clinical feasibility study in the United States